EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging paradigms and recent progress in targeting ErbB in cancers

Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, Isabelle Van Seuningen

Trends in Pharmacological Sciences · 2024

DOI: 10.1016/j.tips.2024.04.009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2024. Verfasst von Nicolas Stoup und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, F…. Hauptthemen laut MEDLINE: Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The epidermal growth factor receptor (EGFR) family is a class of transmembrane proteins, highly regarded as anticancer targets due to their pivotal role in various malignancies. Standard cancer treatments targeting the ErbB receptors include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Despite their substantial survival benefits, the achievement of curative outcomes is hindered by acquired resistance. Recent advancements in anti-ErbB approaches, such as inhibitory peptides, nanobodies, targeted-protein degradation strategies, and bispecific antibodies (BsAbs), aim to overcome such resistance. More recently, emerging insights into the cell surface interactome of the ErbB family open new avenues for modulating ErbB signaling by targeting specific domains of ErbB partners. Here, we review recent progress in ErbB targeting and elucidate emerging paradigms that underscore the significance of EGF domain-containing proteins (EDCPs) as new ErbB-targeting pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsErbB ReceptorsHumansAnimalsAntineoplastic AgentsProtein Kinase InhibitorsMolecular Targeted TherapySignal Transduction

Stichwörter der Autor:innen

EGF-like domainsErbBsdrug resistanceinteractomeoncologytherapeutic targeting

Substanzen

ErbB ReceptorsAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • University of Lille, Inserm, CHU Lille, UMR-S 1172 - LiNC -Lille Neuroscience & Cognition, F-59000 Lille, France.
  • University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France. Electronic address: isabelle.vanseuningen@inserm.fr.

Zitieren

APA

Stoup, N., Liberelle, M., Lebègue, N., & Van Seuningen, I. (2024). Emerging paradigms and recent progress in targeting ErbB in cancers. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2024.04.009

Vancouver

Stoup N, Liberelle M, Lebègue N, Van Seuningen I. Emerging paradigms and recent progress in targeting ErbB in cancers. Trends in Pharmacological Sciences. 2024. doi:10.1016/j.tips.2024.04.009

BibTeX
@article{Stoup2024,
  author = {Stoup, Nicolas and Liberelle, Maxime and Lebègue, Nicolas and Van Seuningen, Isabelle},
  title = {Emerging paradigms and recent progress in targeting ErbB in cancers},
  journal = {Trends in Pharmacological Sciences},
  year = {2024},
  doi = {10.1016/j.tips.2024.04.009}
}
Kostenlos starten →